The acquisition represents a part of Farmak’s international expansion strategy “Farmak 2.0: From local to global success”. This M&A is an important next step after last year’s acquisitions in the Czech Republic and Slovakia. It expands Farmak’s market share and strengthens its position in diabetology, nervous systems, and women health segments in the EU.
The transaction is a result of a thorough preparation and evaluation of different options in the Polish market. The acquired target business fully complies with the legal requirements and high ethical and corporate standards of Farmak. The closing took place after fulfilling the deal conditions and the relevant regulatory requirements.
About Farmak
Farmak pharmaceutical company operates with a focus on research and development, manufacturing, and global sales and marketing of generics. By developing manufacturing and R&D facilities in Ukraine and Spain, Farmak has reached a strong presence globally. The company owns 10 commercial offices strategically positioned around the world, including Ukraine, Poland, the Czech Republic, Slovakia, Central Asia, the Asia Pacific region, the Middle East, and Western Europe. This extensive network underscores Farmak’s commitment to drive quality medicines worldwide.
About Symphar
Symphar is a Polish pharmaceutical marketing company with an office in Warsaw. Its team of 90 professionals works with more than 50 products in the diabetology, gynecology, psychiatry, and neurology areas. In 2023, Symphar reached over EUR 22m revenue following its long-lasting period of stable and profitable growth.
Advisers
FinPoint investment banking firm has acted as an exclusive financial adviser to Farmak on the acquisition.
Swiss Merchant Corporation SA, a Swiss group specialized in private equity investments and M&A transactions, has acted as an exclusive financial adviser to the seller.
